Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $75 to $84
The Battle Brewing Over Blood Tests for Cancer -- Heard on the Street -- WSJ
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences' New Test Positively Identifies More Than 88% of Cases of Colorectal Cancer, Company Says
ESMO 2024: Exact Sciences Unveils Results From Cancer Algorithm Trial
Exas Science Shares Are Trading Higher After the Company Announced Data for Its Blood-based Colorectal Cancer Screening Test.
S&P 500 Futures Flat In Premarket Trading; Nuvalent, Bausch + Lomb Lead
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Exact Sciences Price Target Maintained With a $75.00/Share by Canaccord Genuity
CCORF Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
Express News | Exact Sciences Corp : Evercore ISI Adds Stock to Its Tactical Outperform List
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $85
Exact Sciences Is Maintained at Overweight by Piper Sandler
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $72
Buy Rating for Exact Sciences: Anticipated Growth From Upcoming Catalysts and Competitive Pricing